Industry Insights
Sep 01, 2026 · 1 min read · 15,472 views
Novo's CEO knows the drugmaker needs to build confidence
D
Daniel Park
Editorial · Sep 01, 2026
LONDON - Many investors were underwhelmed by Novo's articulation of its strategy at the company's capital markets day on Monday, and Mike Doustdar knows it. "In some ways, it's good that it's out
← Previous
Scholar Rock gets FDA nod for spinal muscular atrophy drug
Next →
Basecamp raises $140M Series C, unveils six-program pipeline in test of its AI
